The following is a summary of “Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

The treatment landscape for BCG-Unresponsive NMIBC CIS in 2024 For bladder cancer, there are various chemotherapy, thermo-chemotherapy and radiation treatments available. In addition, the U.S ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

“Patients with BCG-naïve high-risk non-muscle invasive bladder cancer have high rates of recurrence and progression,” said Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic ...

In bladder cancer, IBRX has worked to pursue approvals ... they will also be pursuing approval of an alternative source of BCG, which is a different can of worms). The bigger news in the ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...